6th Annual Achieving Quality & Process Excellence in the Pharmaceutical Industry

Jacob Fleming Conferences15-17 September 2010, Lisbon, Portugal.
What are the best practices to achieve QC Laboratory Excellence? How successful are you in adopting and sustaining consistent, harmonized & compliant quality systems?

Leading Pharmaceutical companies will share their first hand experience with transforming the mindset of people, creating the culture of change and continuous improvement in both Quality and Operational Excellence.

Understand, what is the future of Quality organization and how is the role of QA & QC changing in 21st century. Learn how & where to deploy and develop measurable quality systems, Quality Risk Management, QbD & PAT.

Reveal, how to achieve and sustain better costs, productivity and speed through lean six sigma, kaizen and continuous improvement projects.

This event will bring together senior industry quality & operational excellence experts from the pharmaceutical industry presenting real life case studies as well as a lot of networking sessions and discussions.

Key speakers:

  • Head PharmOps QA, Novartis, Switzerland
  • Director/Senior Operational Excellence Leader EMEA, Pfizer, USA
  • Global Head Integrated Risk Management, Pharma Technical Operations - Supply Chain, Roche, Switzerland
  • Vice President Quality, Genzyme, Ireland
  • Head Quality Control Department, Teva, Hungary
  • Head Corporate Quality Assurance,UCB, Belgium
  • Vice President Biopharma Operations, Boehringer Ingelheim, Germany
  • Quality Assurance EMACM, (European, Middle Eastern & African Contract Mfg), Eli Lilly, Italy
  • Head GLP QA, MerckSerono, Italy

Key topics:

  • Case studies on deploying, sustaining & improving consistent, harmonized & compliant quality systems
  • Reveal the future of Quality Organization – interaction between lean & quality in the lab, and changing role of QA & QC in the 21st century
  • Achieving quicker adoption and less ambiguity surrounding ICH Q 8, Q 9 and Q 10 guidance
  • Explore current developments and future trends in Quality by Design & PAT
  • Critical insights on Quality Risk Management
  • Exploit the pathway to compliance based Operational Excellence & Process Improvements – Lean Six Sigma, Kaizen & Continuous Improvement Journey
  • Improving Quality at Contract Manufacturers – real life case studies

Who should attend:
Vice Presidents, Heads, Directors, Senior Managers and Managers of:
Quality Management, Quality Assurance, Quality Operations, Quality Control, Quality Systems, Contract Manufacturing, Operational Excellence, Supply Chain, GMP Compliance, Innovation, PAT, Lean/SixSigma, Lean Manufacturing, API manufacturing, Technical operations, Business Process Management

For further information and registration, please visit:
http://www.jacobfleming.com/jacob-fleming-group/conferences/life-science/6thPharmaQuality

About the Jacob Fleming Conferences
Jacob Fleming Conferences have always been carefully designed to provide key strategic business information and the best networking opportunities for the participants. This young, dynamically growing company provides events for specialized industries including Finance, Life Science, Telecommunications, Chemical, and cross industry sectors. Extensive research, targeted speaker selection and top class venues provide a unique incentive and exceptional opportunities for the executives and experts participating in Jacob Fleming conferences. For more information, visit www.jacobfleming.com.

Most Popular Now

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...